vTv Therapeutics
VTVT
21 hedge funds and large institutions have $8.74M invested in vTv Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.53% more ownership
Funds ownership: 21.9% → 22.43% (+0.53%)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
12% less capital invested
Capital invested by funds: $9.9M → $8.74M (-$1.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$276K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.6K |
| 3 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$6.14K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.2K |
| 5 |
BlackRock
New York
|
+$2.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$21.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.82K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$6.21K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$147 |
| 5 |
JP Morgan Chase
New York
|
-$52 |
VTVT Hedge Fund Activity: Q2 2025 in Review
21 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q2 2025, worth a combined $8.74M — down 12% from $9.9M a quarter earlier.
Fund positioning in VTVT was balanced in Q2 2025: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $276K. The largest seller was UBS Group, cutting an estimated $21.9K.
- 21 institutional investors held vTv Therapeutics (VTVT) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $8.74M of vTv Therapeutics stock for Q2 2025, down 12% quarter-over-quarter.
- 3 funds opened new vTv Therapeutics positions in Q2 2025 and 3 closed out, a net change of 0 holders.
- The largest vTv Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $276K added.
- The largest vTv Therapeutics seller in Q2 2025 was UBS Group, an estimated $21.9K sold.
Based on aggregated 13F filings for Q2 2025.